作者: Osmosis 時(shí)間: 2025-3-21 21:52
Tissue-Specific Delivery of Oligonucleotidesl to the current CRISPR-Cas9 system offering gene editing at the genomic level, oligonucleotides, in addition to their biological functions in storing and conveying genetic information, provide the most prominent solutions to targeted gene therapies. Nonetheless, looking into the future of curing ca作者: CHECK 時(shí)間: 2025-3-22 03:31
Designing siRNA and Evaluating Its Effect on RNA Targets Using qPCR and Western Blotunderstanding of gene function. Carefully designed siRNAs can considerably improve siRNA specificity leading to more accurate and efficient gene silencing. Evaluation of gene knockdown is vital for optimization of siRNA efficacy. Here we describe the fundamental principles of siRNA design and strate作者: 貪婪地吃 時(shí)間: 2025-3-22 08:31 作者: Notorious 時(shí)間: 2025-3-22 12:46
Assessing Oligonucleotide Binding to Double-Stranded DNAc approaches. Several methods can be used to evaluate ONs effect and binding capacity to their target sequence. Here we describe some of the methods, which have been frequently used for assessing ONs binding to dsDNA.作者: refraction 時(shí)間: 2025-3-22 13:27
Modeling and Simulation of Oligonucleotide Hybrids: Outlining a Strategyres of biomolecules. Effects of chemical modifications and of the environment such as sequence, solvent, and ionic strength can explicitly be taken into account. Molecular simulation techniques can also provide insight in change in binding affinity, in protonation (p. shift) and tautomeric propensit作者: 屈尊 時(shí)間: 2025-3-22 18:09 作者: 600 時(shí)間: 2025-3-22 22:12 作者: Liability 時(shí)間: 2025-3-23 02:59
Attachment of Peptides to Oligonucleotides on Solid Support Using Copper(I)-Catalyzed Huisgen 1,3-Di ONs with cell penetrating, homing or endosomal escape peptides can enhance specificity and/or uptake efficiencies. We describe here a general procedure for the preparation of peptide–oligonucleotide conjugates (POCs) on solid support utilizing a novel activated alkyne containing linker which enhanc作者: 小平面 時(shí)間: 2025-3-23 08:11
Characterizing Oligonucleotide Uptake in Cultured Cells: A Case Study Using AS1411 Aptamer of the target. The therapeutic potential of oligonucleotides targeted to intracellular molecules will depend largely on their ability to be taken up by the cells of interest, as well as their subsequent subcellular distribution. Here we describe methods to characterize the extent and mechanism of c作者: 健壯 時(shí)間: 2025-3-23 12:16
Measuring the Action of Oligonucleotide Therapeutics in the Lung at the Cell Type-Specific Level by s from cell culture to in vivo models and the clinic. For example, classical preclinical approaches routinely report 20–60% target knockdown effects in the lung, where 1 or 2 log effects are observed in isolated cell cultures in vitro. Preparation of monocellular suspensions of tissues by mechanoenz作者: TRUST 時(shí)間: 2025-3-23 14:27
Delivery of Antisense Oligonucleotides Mediated by a Hydrogel System: In Vitro and In Vivo Applicatie or RNA interference based drugs, as they can potentially reduce systemic toxicity and enhance in vivo efficacy by increasing in situ concentrations. Here we describe the preparation of antisense oligonucleotide-loaded fibrin hydrogels exploring their applications in the context of the nervous syst作者: deriver 時(shí)間: 2025-3-23 20:39
Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy is its bioavailability for in vivo and in vitro studies. To overcome this challenge we use cell-penetrating peptides (CPPs) for systemic delivery of ASOs. One of the most advanced clinical uses of ASOs is for the treatment of spinal muscular atrophy (SMA). In this chapter, we describe the techniq作者: 極大的痛苦 時(shí)間: 2025-3-23 23:48 作者: 排名真古怪 時(shí)間: 2025-3-24 04:45
In Vitro Assessment of the Hepatotoxicity Potential of Therapeutic Oligonucleotidesmostly investigated directly in rodent studies. A predictive preclinical in vitro model that is capturing liver liabilities of antisense oligonucleotides can be of great help to be used as a first filter in the screening process of therapeutic oligonucleotides. We describe here an in vitro cytotoxic作者: 不確定 時(shí)間: 2025-3-24 09:11 作者: 猜忌 時(shí)間: 2025-3-24 14:10 作者: TOXIN 時(shí)間: 2025-3-24 15:31 作者: 歸功于 時(shí)間: 2025-3-24 21:51 作者: JIBE 時(shí)間: 2025-3-25 02:24
Karin E. Lundin,Olof Gissberg,C. I. Edvard Smith,Rula Zain-30% der Unternehmen elektronische Marktpl?tze nutzen [BaHP03; EUCO03, 28; EUCO05a, 30; GNEK06, 363 ff., 397; PROZ05, 3] und darüber hinaus weitere Unternehmen in den kommenden Jahren deren Einsatz planen [OBKM02, 33; PROZ05, 3]. Insgesamt gehen Unternehmen von einer intensiveren Nutzung elektronisc作者: 束縛 時(shí)間: 2025-3-25 05:12 作者: 種類 時(shí)間: 2025-3-25 07:39 作者: locus-ceruleus 時(shí)間: 2025-3-25 13:31 作者: 燦爛 時(shí)間: 2025-3-25 19:35 作者: echnic 時(shí)間: 2025-3-25 23:03
Negin Mozafari,Tea Umekhl der übernahmen vervielfacht. Dennoch liegen bisher kaum fundierte Erkenntnisse über die Auswirkungen von übernahmen aus unternehmerischer Perspektive und über die Motive des Managements für die eingeschlagenen Strategien vor...Thomas W. Thomas untersucht die Auswirkungen von 529 übernahmen nordam作者: 節(jié)約 時(shí)間: 2025-3-26 02:50 作者: myalgia 時(shí)間: 2025-3-26 08:01 作者: 保守黨 時(shí)間: 2025-3-26 11:14 作者: certain 時(shí)間: 2025-3-26 13:17 作者: Mundane 時(shí)間: 2025-3-26 17:05
Elsa M. Reyes-Reyes,Paula J. Batesverdeutlicht, dass unsere Gesellschaft und die Art, wie wir miteinander kommunizieren, einer steten Ver?nderung unterzogen ist, die durch die Einführung neuer Technologien hervorgerufen wird. Diese Ver?nderungen beschreibt . als ?message“, denen ein ?medium“ vorauseilt. Für den Autor folgt daraus im作者: EXCEL 時(shí)間: 2025-3-26 22:05 作者: 胡言亂語 時(shí)間: 2025-3-27 04:10
Pedro M. D. Moreno,Teresa Rodrigues,Marília Torrado,Isabel F. Amaral,Ana P. Pêgohungen zwischen diesen Variablen in einem Strukturmodell abbilden zu k?nnen, ist in einem vorausgehenden Schritt die Operationalisierung mittels eines Messmodells n?tig (vgl. ./. 1982, S. 453). Hierzu sind dem jeweils interessierenden Konstrukt in der Regel mehrere beobachtbare Variablen zuzuordnen,作者: GRAZE 時(shí)間: 2025-3-27 05:44
Suzan M. Hammond,Frank Abendroth,Michael J. Gait,Matthew J. A. Woodhungen zwischen diesen Variablen in einem Strukturmodell abbilden zu k?nnen, ist in einem vorausgehenden Schritt die Operationalisierung mittels eines Messmodells n?tig (vgl. ./. 1982, S. 453). Hierzu sind dem jeweils interessierenden Konstrukt in der Regel mehrere beobachtbare Variablen zuzuordnen,作者: 改良 時(shí)間: 2025-3-27 12:14 作者: 咆哮 時(shí)間: 2025-3-27 15:35 作者: 演繹 時(shí)間: 2025-3-27 20:50 作者: 不能妥協(xié) 時(shí)間: 2025-3-28 01:49 作者: 方舟 時(shí)間: 2025-3-28 03:28 作者: 拔出 時(shí)間: 2025-3-28 08:51 作者: reserve 時(shí)間: 2025-3-28 10:42
Characterization of Peptide–Oligonucleotide Complexes Using Electron Microscopy, Dynamic Light Scattols for characterizing the shape and size and surface charge of peptide/ON NP by negative staining transmission electron microscopy (TEM) and dynamic light scattering (DLS) respectively, and analysis of NP stability against proteolytic degradation.作者: COMA 時(shí)間: 2025-3-28 16:44 作者: Gesture 時(shí)間: 2025-3-28 20:20
Chemical Development of Therapeutic Oligonucleotides. Here we discuss selected chemistries used in antisense oligonucleotide (ASO) applications (e.g., small interfering RNA (siRNA), RNase H activation, translational block, splice-switching, and also as aptamers). Recently approved oligonucleotide-based drugs are also presented briefly.作者: Pastry 時(shí)間: 2025-3-29 00:30 作者: 獸群 時(shí)間: 2025-3-29 05:20
Delivery of Antisense Oligonucleotides Mediated by a Hydrogel System: In Vitro and In Vivo Applicati Here we describe the preparation of antisense oligonucleotide-loaded fibrin hydrogels exploring their applications in the context of the nervous system utilizing an organotypic dorsal root ganglion explant in vitro system and an in vivo model of spinal cord injury.作者: 仲裁者 時(shí)間: 2025-3-29 10:02
Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficaf ASOs. One of the most advanced clinical uses of ASOs is for the treatment of spinal muscular atrophy (SMA). In this chapter, we describe the techniques used for in vitro screening and analysing in vivo biodistribution of CPP-conjugated ASOs targeting the survival motor neuron 2, ., the dose-dependent modifying gene for SMA.作者: onlooker 時(shí)間: 2025-3-29 13:09
Identifying Suitable Target Regions and Analyzing Off-Target Effects of Therapeutic Oligonucleotidesprogramming language R, and the calculations and data processing can be carried out on a desktop computer. Our workflow integrates well-established data resources and RNA structure-prediction tools and can be modified easily and expanded as new resources become available.作者: 鉆孔 時(shí)間: 2025-3-29 16:39 作者: 牲畜欄 時(shí)間: 2025-3-29 21:34 作者: 偽善 時(shí)間: 2025-3-30 00:30 作者: Eeg332 時(shí)間: 2025-3-30 06:58
pitalkosten, Kapitalstruktur, Steuers?tzen, Umsatzver?nderungen und -wachstum verdeutlichen, dass auch bei ?hnlich gro?en Unternehmen, die Differenz zwischen Steuer- und Marktwerten stark schwankt. Es zeigt sich, dass das Stuttgarter Verfahren nicht immer zu einer Unterbewertung führt, sondern für s作者: 駕駛 時(shí)間: 2025-3-30 10:50 作者: 高談闊論 時(shí)間: 2025-3-30 14:08 作者: 命令變成大炮 時(shí)間: 2025-3-30 18:42 作者: intertwine 時(shí)間: 2025-3-30 22:43 作者: 沙文主義 時(shí)間: 2025-3-31 02:39 作者: BOLT 時(shí)間: 2025-3-31 05:11
Negin Mozafari,Tea Umekin der Gesamtbetrachtung zu einer Wertsteigerung geführt haben, da die Zielunternehmen im gleichen Zeitraum einen Wertzuwachs erfahren haben. Neben dem Ausbau der Marktmacht identifiziert der Autor insbesondere finanzielle Synergien als wichtiges Motiv für die übernahmen...作者: 有害 時(shí)間: 2025-3-31 11:44
Lennart Nilsson,Alessandra Villa to my knowledge - the first empirical comparative analysis of the Sarbanes Oxley Act and the revised 8 EU- Directive. As both statutes provide representative examples for rules-based (Sarbanes-Oxley-Act) and for principles-oriented (8 EU-directive) regulation, this work deserves recognition from be作者: CLOT 時(shí)間: 2025-3-31 14:11
